Helius Medical highlights results of new study on PoNS

Helius Medical (HSDT) Technologies announced it will highlight the results of a new study confirming the therapeutic regimen and sustained efficacy of its Portable Neuromodulation Stimulator, PoNS, device for people with multiple sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting. The event runs from May 28-31 at the Phoenix Convention Center in Phoenix. PoNSTEP’s key finding is that stronger adherence to PoNS Therapya, which combines non-invasive cranial nerve translingual neuro-stimulation with specific physical exercises, results in better therapeutic outcomes. The most-adherent participants maintained superior gait improvement from the end of the study’s supervised therapy phase through its unsupervised therapy phase, achieving a gain of over 6 points in their Dynamic Gait Index scores – a key clinical measurement of walking function and balance – over the first 14 weeks of the trial. PoNSTEP data also show gait improvement levels are durable, sustained at 6 months post-treatment.